Pulse Biosciences (NASDAQ:PLSE) Trading 8% Higher – What’s Next?

Pulse Biosciences, Inc (NASDAQ:PLSE) shares rose 8% on Tuesday . The company traded as high as $19.69 and last traded at $19.7160. Approximately 215,063 shares changed hands during mid-day trading, a decline of 39% from the average daily volume of 352,664 shares. The stock had previously closed at $18.25.

Wall Street Analyst Weigh In

A number of analysts have recently commented on PLSE shares. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 21st. Oppenheimer reiterated an “outperform” rating and set a $30.00 price objective on shares of Pulse Biosciences in a research note on Friday, February 20th. Mizuho set a $30.00 target price on Pulse Biosciences in a research note on Friday, February 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $30.00.

Pulse Biosciences Price Performance

The firm’s 50 day moving average price is $17.27 and its 200-day moving average price is $16.32. The stock has a market cap of $1.32 billion, a P/E ratio of -17.97 and a beta of 1.73.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Thursday, February 19th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.06.

Insider Buying and Selling at Pulse Biosciences

In other news, insider Kevin Patrick Danahy sold 20,000 shares of the business’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $23.53, for a total value of $470,600.00. Following the completion of the transaction, the insider owned 43,298 shares in the company, valued at $1,018,801.94. The trade was a 31.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 85,000 shares of company stock valued at $1,994,400 in the last three months. 74.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Pulse Biosciences

Several large investors have recently bought and sold shares of PLSE. Tudor Investment Corp ET AL purchased a new position in Pulse Biosciences in the 4th quarter worth about $382,000. Inspire Investing LLC boosted its holdings in shares of Pulse Biosciences by 33.4% during the 4th quarter. Inspire Investing LLC now owns 34,192 shares of the company’s stock valued at $469,000 after acquiring an additional 8,561 shares during the last quarter. California State Teachers Retirement System boosted its holdings in shares of Pulse Biosciences by 23.2% during the 4th quarter. California State Teachers Retirement System now owns 21,165 shares of the company’s stock valued at $291,000 after acquiring an additional 3,991 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after acquiring an additional 619 shares during the period. Finally, ExodusPoint Capital Management LP raised its holdings in shares of Pulse Biosciences by 14.9% during the fourth quarter. ExodusPoint Capital Management LP now owns 25,122 shares of the company’s stock valued at $345,000 after purchasing an additional 3,258 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.